Since this is a descriptive study, further clinical investigations are needed to determine whether claudin-5 is correlated with development and progression of cutaneous SCC in EV patients, which could allow its use as a tumor biomarker. This evidence concerns the gene CLDN5 and epidermodysplasia verruciformis.